Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 3, 2015, Pages 685-698

  Krüger, Katharina ^a   Thomale, Jürgen ^b   Stojanović, Nikolina ^c   Osmak, Maja ^c   Henninger, Christian ^a   Bormann, Stefanie ^a   Fritz, Gerhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

DNA damage response; Nephrotoxicity; Normal tissue damage; Platinating anticancer drugs

Indexed keywords

CARBOPLATIN; CASPASE 3; CASPASE 7; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; HISTONE H2AX; OXALIPLATIN; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA ADDUCT; PLATINUM COMPLEX;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; EPITHELIUM CELL; EXCISION REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLOMERULAR ENDOTHELIAL CELL; IC50; IMMUNOFLUORESCENCE; IMPEDANCE; KIDNEY CELL; KIDNEY INJURY; MITOSIS INDEX; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RENAL TUBULAR EPITHELIAL CELL; S PHASE CELL CYCLE CHECKPOINT; STRESS; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL CYCLE; CYTOLOGY; DRUG EFFECTS; GENETICS; GLOMERULUS; KIDNEY TUBULE; METABOLISM;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; ENDOTHELIAL CELLS; KIDNEY GLOMERULUS; KIDNEY TUBULES; ORGANOPLATINUM COMPOUNDS; RATS;

EID: 84921284166     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.12.033     Document Type: Article

References (66)

1. Rosenberg B., VanCamp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
2. Ali I., Wani W.A., Saleem K., Haque A. Platinum compounds: a hope for future cancer chemotherapy. Anti Cancer Agents Med. Chem. 2013, 13:296-306.
3. Pabla N., Murphy R.F., Liu K., Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Ren. Physiol. 2009, 296:F505-F511.
4. Yonezawa A., Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol. 2011, 81:563-568.
5. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14298-14302.
6. Ishida S., McCormick F., Smith-McCune K., Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
7. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstadt H., Lanvers-Kaminsky C., am Zehnhoff-Dinnesen A., Schinkel A.H., Koepsell H., Jurgens H., Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176:1169-1180.
8. Rebillard A., Lagadic-Gossmann D., Dimanche-Boitrel M.T. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr. Med. Chem. 2008, 15:2656-2663.
9. Koberle B., Tomicic M.T., Usanova S., Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta 2010, 1806:172-182.
10. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99:2467-2498.
11. Takahara P.M., Rosenzweig A.C., Frederick C.A., Lippard S.J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995, 377:649-652.
12. Mello J.A., Lippard S.J., Essigmann J.M. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 1995, 34:14783-14791.
13. Cohen S.M., Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 2001, 67:93-130.
14. Roos W.P., Kaina B. DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2012, 332:237-248.
15. Wagstaff A.J., Ward A., Benfield P., Heel R.C. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989, 37:162-190.
16. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 2002, 1:227-235.
17. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., Castedo M., Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
18. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
19. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 1995, 20:435-439.
20. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
21. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002, 62:4899-4902.
22. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., Soria J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.
23. Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., Kratzke R., Douillard J.Y., Seymour L., Pirker R., Filipits M., Andre F., Solary E., Ponsonnailles F., Robin A., Stoclin A., Dorvault N., Commo F., Adam J., Vanhecke E., Saulnier P., Thomale J., Le Chevalier T., Dunant A., Rousseau V., Le Teuff G., Brambilla E., Soria J.C. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 2013, 368:1101-1110.
24. Koberle B., Masters J.R., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 1999, 9:273-276.
25. Koberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., Masters J.R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer 1997, 70:551-555.
26. Masters J.R., Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat. Rev. Cancer 2003, 3:517-525.
27. Welsh C., Day R., McGurk C., Masters J.R., Wood R.D., Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 2004, 110:352-361.
28. Nehme A., Baskaran R., Nebel S., Fink D., Howell S.B., Wang J.Y., Christen R.D. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br. J. Cancer 1999, 79:1104-1110.
29. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
30. Hartmann J.T., Lipp H.P. Toxicity of platinum compounds. Expert. Opin. Pharmacother. 2003, 4:889-901.
31. Yonezawa A., Masuda S., Nishihara K., Yano I., Katsura T., Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 2005, 70:1823-1831.
32. Owatari S., Akune S., Komatsu M., Ikeda R., Firth S.D., Che X.F., Yamamoto M., Tsujikawa K., Kitazono M., Ishizawa T., Takeuchi T., Aikou T., Mercer J.F., Akiyama S., Furukawa T. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007, 67:4860-4868.
33. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57:3537-3547.
34. Dzagnidze A., Katsarava Z., Makhalova J., Liedert B., Yoon M.S., Kaube H., Limmroth V., Thomale J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 2007, 27:9451-9457.
35. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
36. Jiang M., Wei Q., Pabla N., Dong G., Wang C.Y., Yang T., Smith S.B., Dong Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem. Pharmacol. 2007, 73:1499-1510.
37. Pabla N., Huang S., Mi Q.S., Daniel R., Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 2008, 283:6572-6583.
38. Filipski K.K., Mathijssen R.H., Mikkelsen T.S., Schinkel A.H., Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86:396-402.
39. Lee S., Moon S.O., Kim W., Sung M.J., Kim D.H., Kang K.P., Jang Y.B., Lee J.E., Jang K.Y., Lee S.Y., Park S.K. Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury. Nephrol. Dial. Transplant. 2006, 21:2085-2095.
40. Khan S.A., Priyamvada S., Khan W., Khan S., Farooq N., Yusufi A.N. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol. Res. 2009, 60:382-391.
41. Aleksunes L.M., Goedken M.J., Rockwell C.E., Thomale J., Manautou J.E., Klaassen C.D. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 2010, 335:2-12.
42. Materna V., Liedert B., Thomale J., Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 2005, 115:393-402.
43. Martinez-Salgado C., Lopez-Hernandez F.J., Lopez-Novoa J.M. Glomerular nephrotoxicity of aminoglycosides. Toxicol. Appl. Pharmacol. 2007, 223:86-98.
44. Remuzzi G., Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int. Suppl. 1995, 52:S70-S74.
45. Clynes R., Dumitru C., Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
46. McCluskey R.T., Klassen J. Immunologically mediated glomerular, tubular and interstitial renal disease. N. Engl. J. Med. 1973, 288:564-570.
47. Sanchez-Gonzalez P.D., Lopez-Hernandez F.J., Lopez-Novoa J.M., Morales A.I. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit. Rev. Toxicol. 2011, 41:803-821.
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
49. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 2000, 267:5421-5426.
50. Olive P.L. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol. 2004, 75:355-373.
51. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
52. Helbig L., Damrot J., Hulsenbeck J., Koberle B., Brozovic A., Osmak M., Fiket Z., Kaina B., Fritz G. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. J. Biol. Chem. 2011, 286:12991-13001.
53. Liedert B., Pluim D., Schellens J., Thomale J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 2006, 34:e47.
54. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
55. Lavin M.F., Kozlov S., Gueven N., Peng C., Birrell G., Chen P., Scott S. Atm and cellular response to DNA damage. Adv. Exp. Med. Biol. 2005, 570:457-476.
56. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 2001, 11:71-77.
57. Stiff T., O'Driscoll M., Rief N., Iwabuchi K., Lobrich M., Jeggo P.A. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004, 64:2390-2396.
58. Thomas J.P., Lautermann J., Liedert B., Seiler F., Thomale J. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol. Pharmacol. 2006, 70:23-29.
59. Blommaert F.A., van Dijk-Knijnenburg H.C., Dijt F.J., den Engelse L., Baan R.A., Berends F., Fichtinger-Schepman A.M. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995, 34:8474-8480.
60. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001, 478:1-21.
61. Woynarowski J.M., Faivre S., Herzig M.C., Arnett B., Chapman W.G., Trevino A.V., Raymond E., Chaney S.G., Vaisman A., Varchenko M., Juniewicz P.E. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 2000, 58:920-927.
62. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998, 54:770-777.
63. Roos W.P., Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013, 332:237-248.
64. Christmann M., Tomicic M.T., Roos W.P., Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003, 193:3-34.
65. Ciarimboli G., Ludwig T., Lang D., Pavenstadt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167:1477-1484.
66. Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014, 34:547-550.